Conference in Review
ESMO 2026 delivered important results across SCLC, molecularly selected NSCLC and immunotherapy. DeLLphi-305 reported a substantial survival benefit from intensified SCLC maintenance, while Krascendo 1 directly compared KRAS G12C inhibitors. SAFFRON and SANOVO advanced EGFR/MET inhibition in distinct treatment settings.
Antibody–drug conjugates (ADCs) were another major theme, with positive results in OptiTROP-Lung04, OptiTROP-Lung06, HERON-Lung01 and PANKU-Lung01, contrasting with the negative SigVie-002 trial. Meanwhile, the final PEARLS analysis and SARON reinforced an important distinction: improved disease control does not necessarily translate into an overall survival benefit.
Across these studies, biomarker selection, comparator choice, treatment toxicity and survival maturity remain central to clinical interpretation.
Practice-changing
SCLC
LBA3 — DeLLphi-305
Tarlatamab–durvalumab significantly improves survival during maintenance
Study: Randomized phase III trial comparing tarlatamab plus durvalumab with durvalumab alone in extensive-stage SCLC without progression after first-line platinum–etoposide–durvalumab.
Key data: Among 563 patients, median OS from maintenance randomization was 21.1 vs 12.7 months; HR 0.42 (95% CI 0.32–0.54). Median PFS was 7.4 vs 1.9 months; HR 0.34 (95% CI 0.28–0.42). Grade ≥3 all-cause adverse events occurred in 46.8% versus 40.6%.
Why it matters: The first randomized survival evidence supporting the addition of DLL3-directed therapy to first-line maintenance in ES-SCLC.
Clinical context & caveats: OS was assessed at a prespecified interim analysis and measured from maintenance randomization. Cytokine-release syndrome occurred in nearly half of combination-treated patients, predominantly grade 1–2, making treatment delivery and monitoring important.
Targeted Therapy
LBA5 — Krascendo 1
Divarasib improves PFS and OS versus established KRAS G12C inhibitors
Study: Randomized phase III comparison of divarasib with sotorasib or adagrasib in previously treated advanced KRAS G12C-mutated NSCLC.
Key data: Median PFS was 9.8 vs 5.7 months; HR 0.58 (95% CI 0.44–0.76). At the first interim OS analysis, median OS was 17.7 vs 12.0 months; HR 0.56 (95% CI 0.41–0.78). Grade 3/4 treatment-related adverse events occurred in 24.6% versus 34.5%.
Why it matters: Unlike indirect comparisons with historical controls, Krascendo 1 directly addresses treatment selection among KRAS G12C inhibitors.
Clinical context & caveats: Only 15 control patients received adagrasib; the pooled comparator result should not be interpreted as an equally robust head-to-head comparison against both drugs.
LBA6 — SAFFRON
Osimertinib–savolitinib improves PFS and final OS after osimertinib progression
Study: Randomized phase III trial comparing osimertinib plus savolitinib with platinum–pemetrexed in EGFR-mutated NSCLC with MET overexpression, amplification or both after progression on osimertinib.
Key data: Among 338 patients, PFS HR was 0.55 (95% CI 0.42–0.72). Final OS HR was 0.68 (95% CI 0.50–0.91). Twelve-month PFS was 36% versus 10%, and twelve-month OS was 70% versus 53%.
Why it matters: Provides randomized survival evidence supporting biomarker-directed inhibition of acquired MET resistance.
Clinical context & caveats: Applicability depends on stringent MET selection: IHC 3+ in ≥90% of tumor cells and/or FISH ≥10 gene copies. These findings should not be generalized to unselected patients progressing on osimertinib.
LBA67 — OptiTROP-Lung04
Final survival analysis confirms sustained benefit with sacituzumab tirumotecan
Study: Randomized phase III comparison of sacituzumab tirumotecan (sac-TMT), a TROP2-directed ADC, with platinum–pemetrexed chemotherapy in advanced EGFR-mutated nonsquamous NSCLC progressing after EGFR-TKI treatment.
Key data: Among 376 patients, final median OS was 25.9 vs 17.4 months; HR 0.69 (95% CI 0.54–0.89), with median follow-up of 32.3 months. Twenty-four-month OS was 54.1% versus 37.2%. An earlier peer-reviewed analysis established significant PFS and interim OS benefits.
Why it matters: The longer follow-up strengthens evidence supporting sac-TMT as an alternative to platinum-based chemotherapy after EGFR-TKI progression.
Clinical context & caveats: The final analysis confirms an already demonstrated OS benefit rather than establishing a new positive endpoint. Its reported P value is nominal, and treatment sequencing relative to other emerging post-EGFR-TKI options remains unresolved.
Metastatic NSCLC
2614O — PERSEE / GFPC 01-2020
Adding chemotherapy to pembrolizumab improves PFS
Study: Randomized phase III trial comparing first-line pembrolizumab plus platinum-based chemotherapy with pembrolizumab alone in advanced NSCLC with PD-L1 ≥50%.
Key data: Among 321 patients, median PFS was 16.1 vs 6.9 months; HR 0.56 (95% CI 0.43–0.74). Median OS was 50.2 vs 29.9 months; HR 0.77 (95% CI 0.56–1.05). Grade ≥3 treatment-related adverse events occurred in 54% versus 19%.
Why it matters: Directly informs the choice between pembrolizumab monotherapy and chemoimmunotherapy in PD-L1-high NSCLC.
Clinical context & caveats: An OS advantage was not established. The substantial PFS improvement must be weighed against markedly increased treatment-related toxicity.
Early-Stage / Adjuvant Immunotherapy
2511O — PEARLS / KEYNOTE-091
Final analysis shows no significant OS benefit from adjuvant pembrolizumab
Study: Final secondary OS analysis of the randomized phase III trial comparing adjuvant pembrolizumab with placebo in completely resected NSCLC.
Key data: Among 1,177 intention-to-treat patients, OS HR was 0.98 (95% CI 0.81–1.18); six-year OS was 68.5% vs 66.4%. Median DFS remained longer with pembrolizumab: 58.7 vs 43.3 months; HR 0.85 (95% CI 0.73–0.98).
Why it matters: This mature follow-up is important for interpreting the clinical significance of adjuvant DFS improvements and discussing treatment benefits with patients.
Clinical context & caveats: A nonsignificant OS result does not demonstrate equivalence or exclude a survival effect. DFS remained favorable, and the trial was not designed to establish OS superiority as its primary objective.
Potentially practice-changing
Targeted Therapy
LBA69 — SANOVO
Adding savolitinib to first-line osimertinib improves PFS in MET-overexpressing NSCLC
Study: China-based, randomized, double-blind phase III trial comparing savolitinib plus osimertinib with placebo plus osimertinib in treatment-naive advanced EGFR-mutated NSCLC with MET overexpression.
Key data: Among 326 patients, median PFS in the overall population was 24.9 vs 13.8 months; HR 0.56 (95% CI 0.43–0.74). In MET IHC 3+ disease, PFS was 24.8 vs 11.1 months; HR 0.45 (95% CI 0.31–0.66). Interim median OS was 44.5 vs 34.9 months; HR 0.48 (95% CI 0.33–0.68), at 40.5% maturity. Grade ≥3 treatment-emergent adverse events occurred in 77.2% versus 38.4%.
Why it matters: Supports further evaluation of upfront dual EGFR/MET inhibition in a molecularly defined population, rather than waiting for acquired MET resistance.
Clinical context & caveats: Conducted entirely in China, with eligibility dependent on specific MET IHC criteria. The OS analysis remains immature, and the substantial increase in severe adverse events is clinically relevant.
LBA72 — HERON-Lung01
HER3-directed ADC improves PFS after EGFR-TKI progression
Study: Randomized phase III trial comparing ruzaltatug rezetecan, a HER3-directed ADC, with platinum–pemetrexed chemotherapy in advanced EGFR-mutated nonsquamous NSCLC following EGFR-TKI progression.
Key data: Among 498 randomized patients, median PFS was 8.3 vs 5.4 months; HR 0.47 (95% CI 0.36–0.60). Grade ≥3 treatment-related adverse events occurred in 41% vs 39%.
Why it matters: Adds another randomized ADC strategy for EGFR-mutated NSCLC after targeted therapy, expanding the evidence beyond TROP2-directed approaches.
Clinical context & caveats: This was a prespecified interim PFS analysis with only 7.7 months' median follow-up. OS remains immature, and the study was conducted entirely in China. One death of unknown cause was considered possibly treatment-related.
LBA71 — PANKU-Lung01
Iza-bren improves PFS after third-generation EGFR-TKI treatment
Study: Randomized phase III trial comparing izalontamab brengitecan (iza-bren), an EGFR×HER3 bispecific ADC, with platinum-based chemotherapy in EGFR-mutated NSCLC after third-generation EGFR-TKI treatment.
Key data: Of 432 randomized patients, 422 entered the modified intention-to-treat analysis. Median PFS was 11.1 vs 5.7 months; HR 0.40 (95% CI 0.31–0.51). Grade ≥3 treatment-related adverse events occurred in 79% vs 62%, with one treatment-related death in each arm.
Why it matters: Provides further randomized evidence for ADC-based treatment after EGFR-TKI progression.
Clinical context & caveats: OS remains interim, and substantial severe toxicity complicates treatment selection. PANKU-Lung01 and HERON-Lung01 should not be compared indirectly to establish a preferred ADC.
Metastatic NSCLC / ADC Combinations
LBA66 — OptiTROP-Lung06
Sac-TMT–pembrolizumab improves PFS in PD-L1-negative disease
Study: Randomized phase III trial comparing sacituzumab tirumotecan plus pembrolizumab with chemotherapy plus pembrolizumab in untreated nonsquamous NSCLC with PD-L1 TPS <1% and no targetable genomic alterations.
Key data: Among 455 patients, median PFS was 15.0 vs 5.7 months; HR 0.49 (95% CI 0.36–0.65). Immature OS HR was 0.58 (95% CI 0.38–0.88). Grade ≥3 adverse events after treatment initiation occurred in 47.6% versus 60.6%.
Why it matters: Provides randomized evidence for replacing the conventional chemotherapy component of first-line chemoimmunotherapy with a TROP2-directed ADC.
Clinical context & caveats: OS remains immature after only 9.7 months of follow-up, and a statistically significant survival benefit should not be inferred from the numerical OS signal.
Early-Stage / Perioperative Therapy
LBA64 — Neotorch
Final stage II/III analysis supports perioperative toripalimab
Study: Updated randomized trial comparing perioperative toripalimab plus chemotherapy with placebo plus chemotherapy in resectable stage II/III NSCLC.
Key data: In the 501-patient population, median EFS was not reached vs 20.2 months; HR 0.52 (95% CI 0.39–0.68). OS HR was 0.66 (95% CI 0.49–0.89), with median OS not reached in either arm. Grade ≥3 treatment-emergent adverse events occurred in 68% versus 57%.
Why it matters: Longer follow-up and the expanded stage II/III analysis strengthen the survival evidence supporting perioperative immunochemotherapy.
Clinical context & caveats: The overall finding does not establish equal benefit across individual stage or PD-L1 subgroups. Applicability also depends on regional treatment availability.
Previously Treated NSCLC / ADC Therapy
LBA68 — SigVie-002
Sigvotatug vedotin fails to improve OS versus docetaxel
Study: Randomized phase III trial comparing sigvotatug vedotin with docetaxel in previously treated nonsquamous NSCLC.
Key data: Among 703 patients, median OS was 11.9 vs 11.5 months; HR 0.929 (95% CI 0.767–1.126). Median PFS was 4.7 vs 4.2 months; HR 0.844 (95% CI 0.699–1.019). Grade ≥3 treatment-related adverse events occurred in 33% versus 36%.
Why it matters: An important negative ADC trial demonstrating that promising early activity does not necessarily translate into survival benefit in phase III testing.
Clinical context & caveats: Exploratory or post hoc subgroup findings cannot overturn the negative primary OS endpoint or establish a validated population benefiting from treatment.
Oligometastatic NSCLC / Local Therapy
2613O — SARON
Consolidation radiotherapy improves PFS without an OS benefit
Study: Randomized phase II trial comparing systemic treatment plus consolidation radiotherapy with systemic treatment alone in synchronous oligometastatic NSCLC.
Key data: Among 140 patients, median OS was 31.0 vs 28.0 months; HR 0.99 (95% CI 0.63–1.55). Median PFS was 13.9 vs 8.9 months; HR 0.64 (95% CI 0.43–0.95). Grade ≥3 adverse events occurred in 28.6% of patients in both arms.
Why it matters: Demonstrates improved disease control with consolidation radiotherapy but no observed OS advantage in this randomized population.
Clinical context & caveats: A small phase II trial using heterogeneous systemic treatments. The absence of an OS benefit does not establish equivalence or exclude benefit in selected subgroups or with contemporary systemic regimens.
Expert Takeaways
Randomized survival evidence is reshaping treatment choices. DeLLphi-305, Krascendo 1 and SAFFRON provide substantial survival results in distinct disease settings, although maturity, biomarker criteria and implementation remain important.
EGFR/MET inhibition is advancing in two settings. SAFFRON addresses acquired MET resistance after osimertinib, while SANOVO investigates upfront dual inhibition in MET-overexpressing disease.
The ADC landscape is expanding, but results are not interchangeable. OptiTROP-Lung04, OptiTROP-Lung06, HERON-Lung01 and PANKU-Lung01 offer encouraging randomized data, while SigVie-002 is a reminder that not every ADC succeeds.
Disease-control benefits do not necessarily translate into OS improvements. PEARLS and SARON illustrate the importance of longer follow-up and careful interpretation of endpoint differences.
Comparative evidence should guide treatment selection. PERSEE and Krascendo 1 directly address existing clinical choices, but toxicity and comparator composition remain essential considerations.
If you found this useful, subscribe to receive next synthesis.
Know a colleague who would benefit? Forward this issue.

Refer a colleague

